Association For Accessible Medicines company information, Employees & Contact Information

AAM Requests Federal Injunction to Block Connecticut’s Unconstitutional Drug Price Law Association for Accessible Medicines

GRx+Biosims Day 1 Recap: Bringing Passion to Purpose Association for Accessible Medicines

AAM Comments on Colorado PDAB Pricing Announcement Association for Accessible Medicines

Generic and Biosimilar Medicines Save $467 Billion in 2024 Association for Accessible Medicines

Lupin Announces New U.S. Manufacturing Facility and $250 Million Domestic Investment Association for Accessible Medicines

Mark Ratner Joins AAM to Lead Government Relations Association for Accessible Medicines

Generic and Biosimilar Patent Settlements Save $423 Billion Association for Accessible Medicines

2025 Generic and Biosimilar Medicines Savings Report Highlights Value and Vulnerability Association for Accessible Medicines

Amphastar to Quadruple Domestic Manufacturing Association for Accessible Medicines

Alex Keeton Named Head of the Biosimilars Council, SVP of Policy Association for Accessible Medicines

Patent Thickets and Litigation Abuses Hinder all Biosimilars Association for Accessible Medicines

AAM Congratulates FDA Commissioner Makary Association for Accessible Medicines

Medicare Drug Price Negotiation has Chilling Effect on Generic and Biosimilar Medicines Development and Availability Association for Accessible Medicines

Report: 2023 U.S. Generic and Biosimilar Medicines Savings Report Association for Accessible Medicines

AAM Congratulates Dr. Tidmarsh on Appointment as Director of CDER Association for Accessible Medicines

Serial Patent Litigation: The Problem is Getting Worse Association for Accessible Medicines

AAM Comments on Section 232 Investigation on Pharmaceuticals Association for Accessible Medicines

Eighth Circuit Court Rules Unanimously for AAM in Generic Pricing Appeal Association for Accessible Medicines

Hikma Breaks Ground on Expanded U.S. Manufacturing and Announces $1 Billion Investment Association for Accessible Medicines

Inflation Reduction Act Association for Accessible Medicines

The IRA Hurts Generic and Biosimilar Medication Competition Association for Accessible Medicines

Access! 2026 – AAM Annual Meeting Association for Accessible Medicines

Report: 2021 U.S. Generic and Biosimilar Medicines Savings Report Association for Accessible Medicines

Association for Accessible Medicines 2025 Advocacy Priorities Association for Accessible Medicines

AAM Commends Senate Q1/Q2 Bill Introduction Association for Accessible Medicines

Patent Settlements Are Necessary To Help Combat Patent Thickets Association for Accessible Medicines

$423B Savings from Patent Settlements Since Actavis Ruling Association for Accessible Medicines

Federal Advocacy Association for Accessible Medicines

AAM Testimony on the Generic Global Supply Chain—Five Takeaways Association for Accessible Medicines

Access! 2025 Recap: A Call to Action for the Future of Generics and Biosimilars Association for Accessible Medicines

AAM Commends Q1/Q2 House Bill Reintroduction Association for Accessible Medicines

AMGEN INC., AMGEN MANUFACTURING LIMITED v. SANDOZ INC. Association for Accessible Medicines

Increase Competition & Access — Support CREATES Act Association for Accessible Medicines

Adding up the Generic Savings for Americans with Cancer and Other Conditions Association for Accessible Medicines

The Generic Drug Supply Chain Association for Accessible Medicines

AAM Statement: New Study Shows Formulary Abuses Force Patients to Pay More for Generic Drugs Even as the Prices of Those Drugs Go Down Association for Accessible Medicines

GRx+Biosims Year 2: The Recap Association for Accessible Medicines

Redesigned Medicare Drug Program Still Allows PBMs to Deny Patients Access to Lower-Cost Generics & Biosimilars Association for Accessible Medicines

Generic Medicines 35th Birthday Celebration Association for Accessible Medicines

AAM Statement on The Protecting Access to Affordable Medicines Act Association for Accessible Medicines

Association for Accessible Medicines Names New President and CEO Association for Accessible Medicines

Patients Are Paying Too Much — Middlemen Are Marking Up Your Generics Association for Accessible Medicines

What They Are Saying – Blocking Access to Samples Association for Accessible Medicines

Stop patent abuse and unleash generic and biosimilar price competition Association for Accessible Medicines

Medicare Plans Increase Patient Costs for Generic Medicines Association for Accessible Medicines

Generics: Your Prescription for Savings Association for Accessible Medicines

NAFTA 2.0: 3 Obstacles to More Affordable Medicines in the U.S. Association for Accessible Medicines

Member Spotlight: Apotex Association for Accessible Medicines

AAM Statement on FDA Record Generic Approvals Association for Accessible Medicines

Paula Witt Joins AAM as Senior Manager, State Government Affairs Association for Accessible Medicines

Restricted Access Drug Programs Impeding Patient Access to Generic Drugs: Myths and Facts Regarding Maine LD 1280 Association for Accessible Medicines

Association for Accessible Medicines (AAM) Elevates David Gaugh to Executive Vice President for Sciences & Regulatory Affairs Association for Accessible Medicines

Generic Drug Competition Lowers Prescription Cost to $6 on Average, Study Finds Association for Accessible Medicines

Congress Should Pass Legislation to End the Shenanigans That Allow Brand-Name Drug Manufacturers to Delay Generic Competition and Charge Higher Prices for Longer Periods Association for Accessible Medicines

Patients Can See Their Savings Association for Accessible Medicines

Scott Kuzner Joins AAM As Senior Director, Sciences and Regulatory Affairs Association for Accessible Medicines

Happy Birthday, Generic Prescription Drugs: 35 Years of Competition Association for Accessible Medicines

Patient Stories: Voices of Access Association for Accessible Medicines

AAM Announces 2020 Board of Directors Association for Accessible Medicines

Generic and Biosimilars Approvals Are Only Half the Story Association for Accessible Medicines

AAM Has Adopted a Code of Business Ethics. Here’s What That Means. Association for Accessible Medicines

Cancer Costs and Options for Care in the United States Association for Accessible Medicines

Tara Ryan Joins AAM as Vice President, State Government Affairs Association for Accessible Medicines

Seeking Asylum for Its Patents on Tribal Lands: The Latest Brand-Name Drug Company Strategy to Preserve Monopoly Pricing Association for Accessible Medicines

AAM’s Karin Hessler Provides an Inside Look at the GRx+Biosims 2019 Legal Track Association for Accessible Medicines

New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption Association for Accessible Medicines

Andrew O’Connor Joins AAM as Manager, State Government Affairs Association for Accessible Medicines

Generic Drug Prices vs. Brand Drug Prices Association for Accessible Medicines

Tariffs & Trade Association for Accessible Medicines

Preserve Patient Access to First Generics Association for Accessible Medicines

AAM Announces 2022 Board of Directors Association for Accessible Medicines

35 Year Anniversary of Generic Medicines Association for Accessible Medicines

Thank you, Jean Hoffman Association for Accessible Medicines

Member Spotlight: Associate Member CMMB’s Global Health Mission Association for Accessible Medicines

Medicaid Generics Penalty Association for Accessible Medicines

PFIZER, INC. v. JOHNSON & JOHNSON and JANSSEN BIOTECH, INC. Association for Accessible Medicines

Senate Finance Committee Bill Addressing Drug Shortages Would Provide Long Overdue Relief from Penalties Hurting Generic Drug Market Association for Accessible Medicines

Competition Matters. That’s Why We Need to Further Improve IPR. Association for Accessible Medicines

Polly Webster Joins AAM As Vice President, Federal Affairs Association for Accessible Medicines

Dispensary of Hope: The Industry’s Nonprofit Supply-Chain Partner Association for Accessible Medicines

GDUFA Reauthorization: A Primer Association for Accessible Medicines

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA, INC., and AKORN INC., Petitioners v. ALLERGAN, INC., Patent Owner Association for Accessible Medicines

Thank You, Bill Haddad Association for Accessible Medicines

Thank you, Agnes Varis Association for Accessible Medicines

Strengthening the U.S. Pharmaceutical Supply Chain: What We Know—and What We Don’t Association for Accessible Medicines

GDUFA/BsUFA User Fees Association for Accessible Medicines

Thank you, Carole Ben-Maimon Association for Accessible Medicines

Prescription Drug Education Program Association for Accessible Medicines

Thank you, Desh Bandhu Gupta Association for Accessible Medicines

Thank you, Rep. Henry Waxman Association for Accessible Medicines

Thank you, Mike Puskar Association for Accessible Medicines

Protect access to affordable medicines in trade agreements. Fix the USMCA. Association for Accessible Medicines

Myths vs. Facts of Biologic Market Exclusivity in Mexico — #FixUSMCA Association for Accessible Medicines

John Murphy Named President and CEO of AAM Association for Accessible Medicines

Giuseppe Randazzo Joins AAM as Vice President, Sciences and Regulatory Affairs Association for Accessible Medicines

Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why? Association for Accessible Medicines

Skyrocketing Drug Prices: What’s Driving Up Costs? Association for Accessible Medicines

Chirag Patel Named Chair of the Association for Accessible Medicines Board of Directors Association for Accessible Medicines

AAM Requests Federal Injunction to Block Illinois’ Unconstitutional Drug Price Law Association for Accessible Medicines

Study Finds U.S. Generic and Biosimilar Savings Totaled A Record $338 Billion in 2020 Association for Accessible Medicines